These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 19544535)
21. Do we need more nomograms for predicting outcomes in patients with prostate cancer? Kattan MW Nat Clin Pract Urol; 2008 Jul; 5(7):366-7. PubMed ID: 18506152 [No Abstract] [Full Text] [Related]
22. Predicting life expectancy in prostate cancer patients. Jeldres C; Latouff JB; Saad F Curr Opin Support Palliat Care; 2009 Sep; 3(3):166-9. PubMed ID: 19553817 [TBL] [Abstract][Full Text] [Related]
23. Sequential testing approach as an efficient and easier alternative for the validation of new predictive technologies in the clinic. Beam CA; Gao W; Macias V; Liang W; Kajdacsy Balla A J Clin Oncol; 2009 Mar; 27(7):1087-90. PubMed ID: 19139434 [TBL] [Abstract][Full Text] [Related]
26. Predictive models of toxicity in external radiotherapy: dosimetric issues. Fiorino C; Rancati T; Valdagni R Cancer; 2009 Jul; 115(13 Suppl):3135-40. PubMed ID: 19544542 [TBL] [Abstract][Full Text] [Related]
27. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Bickers B; Aukim-Hastie C Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347 [TBL] [Abstract][Full Text] [Related]
28. [Epidemiology, diagnosis and prognosis of localized prostate cancer: what's new?]. Drouin SJ; Rouprêt M Prog Urol; 2009 Apr; 19 Suppl 1():S3-7. PubMed ID: 19465334 [TBL] [Abstract][Full Text] [Related]
29. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Armstrong AJ; Febbo PG Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076 [TBL] [Abstract][Full Text] [Related]
30. A graphical device to represent the outcomes of a logistic regression analysis. Kranse R; Roobol M; Schröder FH Prostate; 2008 Nov; 68(15):1674-80. PubMed ID: 18712715 [TBL] [Abstract][Full Text] [Related]
31. Computerized utility assessment for cancer decision making: promises and pitfalls. Saigal CS Cancer Invest; 2009 Nov; 27(9):937-41. PubMed ID: 19832042 [No Abstract] [Full Text] [Related]
32. Clinical and diagnostic assessment for therapeutic decisions in prostate cancer. Passoni NM; Di Trapani E; Suardi N; Gallina A; Abdollah F; Bianchi M; Picchio M; Giovacchini G; Messa C; Rigatti P; Montorsi F; Briganti A Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):321-30. PubMed ID: 23013662 [TBL] [Abstract][Full Text] [Related]
33. A framework for the identification of men at increased risk for prostate cancer. Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625 [TBL] [Abstract][Full Text] [Related]
34. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Denham JW; Steigler A; Wilcox C; Lamb DS; Joseph D; Atkinson C; Tai KH; Spry NA; Gleeson PS; D'Este C Cancer; 2009 Oct; 115(19):4477-87. PubMed ID: 19691097 [TBL] [Abstract][Full Text] [Related]
35. [Treatment of localized prostate cancer having a good prognosis may cause more harm than benefit]. Ruutu M; Rannikko A; Malmi H; Vasarainen H; Mikkola A Duodecim; 2009; 125(14):1516-23. PubMed ID: 19711574 [TBL] [Abstract][Full Text] [Related]
36. A multidisciplinary prostate cancer clinic for newly diagnosed patients: developing the role of the advanced practice nurse. Madsen LT; Craig C; Kuban D Clin J Oncol Nurs; 2009 Jun; 13(3):305-9. PubMed ID: 19502188 [TBL] [Abstract][Full Text] [Related]
37. Prostate specific antigen best practice statement: 2009 update. Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717 [TBL] [Abstract][Full Text] [Related]